ClinicalTrials.gg
CompletedNCT00803101BE1116_3003Updated Apr 6, 2015Results posted

An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure

A Phase 3 interventional study of Beriplex® P/N (Kcentra) and Fresh frozen plasma in Reversal of Coagulopathy, sponsored by CSL Behring. Completed at 30 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-06.

Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Hemophilia B by CSL Limited — 4 open to participants now, 5 under way, 2 of them phase 3. Hemophilia B · CSL Limited.

Enrollment
Largest of 14
176 · median 26
Started
2009
the only one that year
Phase 3
8 of 18
2 open now
Registered
2nd of 18
by date

Among the 18 studies in Hemophilia B by CSL Limited, this one has the largest enrollment of the 14 interventional ones that give a count, is the only one that started in 2009, is one of 8 in phase 3, and was the 2nd registered.

Hemophilia B

292 studies on the registry are indexed under Hemophilia B; 51 are open to participants now.

Browse Hemophilia B studies →

Open to participants now

4 of the 18 studies in Hemophilia B by CSL Limited are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 30 Hemophilia B studies recruiting now, 17 (57%) set no upper age limit and 11 (37%) stop at 75 or younger; 16 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Hemophilia B by CSL Limited, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate efficacy, safety and tolerance of Beriplex® P/N (Kcentra) compared with plasma in regard to rapid reversal of coagulopathy induced by vitamin K antagonists in subjects who require immediate correction of international normalized ratio (INR) because of emergency surgery.

03

Conditions studied

  • Reversal of Coagulopathy

Keywords

  • Anticoagulant reversal
  • Prothrombin Complex Concentrate
  • Coagulopathy
  • Coumarin derivatives
  • Emergency surgery
  • Invasive procedures
  • Vitamin K
  • Reversal of coagulopathy induced by coumarin derivatives
  • Kcentra
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects greater than or equal to 18 years,
  • Subjects currently on oral vitamin K antagonist (VKA) therapy,
  • An urgent surgical procedure is required within 24 hours of the start of medicinal product (IMP),
  • Due to the nature of the procedure, withdrawal of oral VKA therapy and infusion of plasma are also indicated to reverse the VKA effect,
  • greater than or equal to 2 within 3 hours before start of IMP,
  • has been obtained.

Exclusion criteria

Exclusion Criteria:

  • Subjects requiring urgent surgical procedures where according to the surgeon's clinical judgment, an accurate estimate of blood loss is not possible (e.g., ruptured aneurysm),
  • Subjects for whom administration of intravenous vitamin K and vitamin K antagonists withdrawal alone can adequately correct the subject's coagulopathy before initiation of the urgent surgical procedure,
  • Administration of intravenous vitamin K more than 3 hours or administration of oral vitamin K more than 6 hours prior to infusion of IMP,
  • Subjects in whom lowering within normal range may present an unacceptable risk for a thromboembolic complication where the INR goal is to lower but not normalize the INR because of risk of a procedure-associated stroke,
  • Subjects, who despite medical management that includes close monitoring and diuretics, may not, by investigator assessment, tolerate the total volume of IMP required by the protocol,
  • Expected need for additional non-study blood products before infusion of IMP (Note: Administration of packed red blood cells is not an exclusion criterion),
  • Expected need for transfusions or desmopressin before Day 10,
  • Acute trauma for which reversal of vitamin K antagonists alone would not be expected to control or resolve an acute bleeding complication and/or control the acute bleeding event,
  • Unfractionated or low molecular weight heparin use within 24 hours before randomization or potential need before completion of the procedure,
  • History of thromboembolic event, myocardial infarction, unstable angina pectoris, critical aortic stenosis, cerebral vascular accident, , severe peripheral vascular disease, disseminated intravascular coagulation within 3 months of enrollment,
  • Reversal of VKA therapy alone may not resolve the coagulopathy (eg, receiving a potent anti-platelet agent, i.e., clopidogrel or prasugrel, or advanced liver disease),
  • Known history of antiphospholipid antibody syndrome or lupus anticoagulant antibodies,
  • Suspected or confirmed serious viral or bacterial infection, e.g., meningitis, or sepsis at time of enrollment,
  • Administration of whole blood, plasma, plasma fractions or platelets within 2 weeks prior to inclusion into the study (Note: Administration of packed red blood cells is not an exclusion criterion),
  • Pre-existing progressive fatal disease with a of less than 2 months,
  • Known inhibitors to coagulation factors II, VII, IX, or X; or hereditary protein C or protein S deficiency; or heparin-induced, type II thrombocytopenia,
  • Treatment with any other medicinal product within 30 days prior to inclusion into the study,
  • Presence or history of to components of the study medication,
  • Pregnant or breast-feeding women,
  • Prior inclusion in this study or any other CSL Behring sponsored Beriplex study,
  • For subjects with intracranial hemorrhage with:

    • Glasgow Coma Score \<10 (see Appendix 8)
    • Modified Rankin Score > 3 prior to ICH (see Appendix 9)
    • Intracerebral hemorrhage
    • Epidural hematomas
    • Infratentorial hemorrhage
    • Subarachnoid hemorrhage (SAH) subjects with a Hunt and Hess Scale >2
    • Subdural hematomas that:

      • are judged to be an acute subdural hematoma (based on neurosurgeon review)
      • have a concurrent SAH or parenchymal contusion
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
176 participants (actual)

Study arms

  • Experimental
    Beriplex® P/N

    Biological: Beriplex® P/N (Kcentra)

  • Active comparator
    Fresh frozen plasma

    Biological: Fresh frozen plasma

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Hemostatic Efficacy During Surgery

    Hemostatic efficacy was rated as excellent, good, or poor/none, based on prespecified definitions. Hemostatic efficacy was the binary endpoint of effective or non-effective hemostasis, where 'effective' was a hemostatic efficacy rating of "excellent" or "good," and 'non-effective' was a hemostatic efficacy rating of "poor/none".

    Time frame: From the start of infusion until the end of surgery

  2. Percentage of Participants Who Had a Rapid Decrease of the INR

    A rapid decrease of the INR was defined as an INR ≤ 1.3 at 30 minutes after the end of infusion. The INR is a standard way to describe the time it takes for blood to clot; an INR range of 0.8 to 1.2 is considered normal for a healthy person who is not using oral anticoagulant therapy.

    Time frame: 30 minutes after the end of infusion

Secondary outcomes

  1. Plasma Levels of Factors II, VII, IX, and X, Protein C, and Protein S

    Plasma levels are presented as the percentage of normal at pre-infusion and 30 min and 24 h after the start of infusion. The plasma level assay results are reported as a potency relative to a standard, where 100% is considered to be normal.

    Time frame: From pre-infusion until 24 h after the start of infusion

  2. Transfusion of Packed Red Blood Cells (PRBCs) or Whole Blood

    The total units of transfused PRBCs or whole blood

    Time frame: From the start of surgery until 24 h after the start of surgery

  3. Percentage of Participants With INR Correction at Various Times After the Start of Infusion

    The time taken from the start of infusion to INR correction (defined as an INR ≤ 1.3) was recorded. The percentage of participants with INR correction was calculated at 0.5, 1, 3, 6, 12, and 24 h after the start of infusion.

    Time frame: From the start of infusion until INR correction; calculated at 0.5, 1, 3, 6, 12, and 24 h after the start of infusion

  4. Percentage of Participants Who Received Red Blood Cells

    Red blood cells were PRBCs and whole blood

    Time frame: From the start of surgery until 24 h after the start of surgery

  5. Overall Treatment-emergent Adverse Events (TEAEs)

    Number of participants with TEAEs. TEAEs were defined as adverse events that developed or worsened following exposure to investigational medicinal product. Treatment-related TEAEs were events whose relationship to study treatment was related, probably related, or possibly related in the opinion of the investigator. Treatment emergent adverse events with missing relationship were considered related to treatment. Serious TEAEs were treatment-emergent serious adverse events (SAEs).

    Time frame: From the start of infusion up to the allowed time window of the Day 10 visit for non-serious AEs and from the start of infusion up to the allowed time window of the Day 45 visit for SAEs

07

Results

Posted Feb 25, 2014

Participant flow

Participant flow — Overall Study
MilestoneBeriplex® P/NFresh Frozen Plasma
Started8888
Completed7066
Not completed1822
Withdrew: Death / serious adverse event46
Withdrew: Withdrawal by subject64
Withdrew: Lost to follow-up22
Withdrew: Protocol violation17
Withdrew: Surgery finished outside protocol window11
Withdrew: Patient died outside sae report period10
Withdrew: Patient did not attend scheduled visit21
Withdrew: Patient did not have surgery11

Outcome measures

PrimaryPercentage of Participants Achieving Hemostatic Efficacy During Surgery

Hemostatic efficacy was rated as excellent, good, or poor/none, based on prespecified definitions. Hemostatic efficacy was the binary endpoint of effective or non-effective hemostasis, where 'effective' was a hemostatic efficacy rating of "excellent" or "good," and 'non-effective' was a hemostatic efficacy rating of "poor/none".

Time frame:
From the start of infusion until the end of surgery
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Hemostatic Efficacy During Surgery
percentage of participantsBeriplex® P/NFresh Frozen Plasma
Percentage of Participants Achieving Hemostatic Efficacy During Surgery89.7 (83.3 to 96.1)75.3 (65.9 to 84.7)
Statistical analysis
  • Beriplex® P/N vs Fresh Frozen Plasma · 95% confidence interval · Difference in effective hemostasis (%): 14.3 · 95% CI 2.8 to 25.8The Newcombe-Wilson score method was used to estimate the 95% CI for the difference (Beriplex-plasma) in the % participants with effective hemostasis
PrimaryPercentage of Participants Who Had a Rapid Decrease of the INR

A rapid decrease of the INR was defined as an INR ≤ 1.3 at 30 minutes after the end of infusion. The INR is a standard way to describe the time it takes for blood to clot; an INR range of 0.8 to 1.2 is considered normal for a healthy person who is not using oral anticoagulant therapy.

Time frame:
30 minutes after the end of infusion
Reported as:
Number · percentage of participants
Percentage of Participants Who Had a Rapid Decrease of the INR
percentage of participantsBeriplex® P/NFresh Frozen Plasma
Percentage of Participants Who Had a Rapid Decrease of the INR55.2 (44.7 to 65.6)9.9 (3.4 to 16.4)
Statistical analysis
  • Beriplex® P/N vs Fresh Frozen Plasma · Newcombe-Wilson score method · Difference in effective hemostasis (%): 45.3 · 95% CI 31.9 to 56.4The Newcombe-Wilson score method was used to estimate the 95% CI for the difference (Beriplex-plasma) in the % pts with rapid decrease of the INR.
SecondaryPlasma Levels of Factors II, VII, IX, and X, Protein C, and Protein S

Plasma levels are presented as the percentage of normal at pre-infusion and 30 min and 24 h after the start of infusion. The plasma level assay results are reported as a potency relative to a standard, where 100% is considered to be normal.

Time frame:
From pre-infusion until 24 h after the start of infusion
Reported as:
Mean · percentage of normal
Plasma Levels of Factors II, VII, IX, and X, Protein C, and Protein S
percentage of normalBeriplex® P/NFresh Frozen Plasma
Factor II, pre-infusion (n = 85; 79)32.0 ± 19.9334.8 ± 26.19
Factor II, 0.5 h after infusion start (n = 71; 73)84.5 ± 20.9242.5 ± 25.71
Factor II, 24 h after infusion start (n = 81; 74)81.4 ± 24.8365.6 ± 23.68
Factor VII, pre-infusion start (n = 85; 79)36.8 ± 59.2731.1 ± 25.16
Factor VII, 0.5h after infusion start (n = 71; 73)60.1 ± 44.9141.6 ± 42.90
Factor VII, 24 h after infusion start (n = 81; 74)85.5 ± 59.7683.7 ± 58.90
Factor IX, pre-infusion (n = 85; 79)48.1 ± 25.6255.8 ± 30.50
Factor IX, 0.5 h after infusion start (n = 71; 73)71.6 ± 25.3856.2 ± 23.12
Factor IX, 24 h after infusion start (n = 81; 74)85.2 ± 33.3993.7 ± 34.25
Factor X, pre-infusion (n = 85; 79)19.3 ± 19.3220.8 ± 21.38
Factor X, 0.5 h after infusion start (n = 71; 73)82.3 ± 23.3329.8 ± 22.51
Factor X, 24 h after infusion start (n = 81; 74)78.3 ± 25.6260.2 ± 22.44
Protein C, pre-infusion (n = 85; 78)48.8 ± 19.0747.6 ± 21.38
Protein C, 0.5 h after infusion start (n = 71; 73)97.1 ± 21.9752.5 ± 18.69
Protein C, 24 h after infusion start (n = 81; 74)87.3 ± 26.2878.1 ± 24.80
Protein S, pre-infusion (n = 85; 79)45.25 ± 18.49846.18 ± 20.986
Protein S, 0.5 h after infusion start (n = 72; 73)80.73 ± 31.48955.82 ± 24.689
Protein S, 24 h after infusion start (n = 82; 74)75.97 ± 36.44969.32 ± 27.504
SecondaryTransfusion of Packed Red Blood Cells (PRBCs) or Whole Blood

The total units of transfused PRBCs or whole blood

Time frame:
From the start of surgery until 24 h after the start of surgery
Reported as:
Mean · units of PRBCs or whole blood
Transfusion of Packed Red Blood Cells (PRBCs) or Whole Blood
units of PRBCs or whole bloodBeriplex® P/NFresh Frozen Plasma
Transfusion of Packed Red Blood Cells (PRBCs) or Whole Blood0.3 ± 0.900.4 ± 1.02
SecondaryPercentage of Participants With INR Correction at Various Times After the Start of Infusion

The time taken from the start of infusion to INR correction (defined as an INR ≤ 1.3) was recorded. The percentage of participants with INR correction was calculated at 0.5, 1, 3, 6, 12, and 24 h after the start of infusion.

Time frame:
From the start of infusion until INR correction; calculated at 0.5, 1, 3, 6, 12, and 24 h after the start of infusion
Reported as:
Number · percentage of participants
Percentage of Participants With INR Correction at Various Times After the Start of Infusion
percentage of participantsBeriplex® P/NFresh Frozen Plasma
0.5 h10
1 h540
3 h7710
6 h8120
12 h8332
24 h8748
SecondaryPercentage of Participants Who Received Red Blood Cells

Red blood cells were PRBCs and whole blood

Time frame:
From the start of surgery until 24 h after the start of surgery
Reported as:
Number · percentage of participants
Percentage of Participants Who Received Red Blood Cells
percentage of participantsBeriplex® P/NFresh Frozen Plasma
Percentage of Participants Who Received Red Blood Cells16.114.8
SecondaryOverall Treatment-emergent Adverse Events (TEAEs)

Number of participants with TEAEs. TEAEs were defined as adverse events that developed or worsened following exposure to investigational medicinal product. Treatment-related TEAEs were events whose relationship to study treatment was related, probably related, or possibly related in the opinion of the investigator. Treatment emergent adverse events with missing relationship were considered related to treatment. Serious TEAEs were treatment-emergent serious adverse events (SAEs).

Time frame:
From the start of infusion up to the allowed time window of the Day 10 visit for non-serious AEs and from the start of infusion up to the allowed time window of the Day 45 visit for SAEs
Reported as:
Number · participants
Overall Treatment-emergent Adverse Events (TEAEs)
participantsBeriplex® P/NFresh Frozen Plasma
Any TEAE4953
At least possibly treatment-related TEAE815
Serious TEAE2223
Death48

Adverse events

Collected over From the start of infusion up to the allowed time window of the Day 10 visit for non-serious AEs and from the start of infusion up to the allowed time window of the Day 45 visit for SAEs.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Beriplex® P/N—22/88 (25%)41/88 (46.6%)
Fresh Frozen Plasma—23/88 (26.1%)44/88 (50%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventBeriplex® P/NFresh Frozen Plasma
Respiratory failureRespiratory, thoracic and mediastinal disorders1/883/88
Gastrointestinal haemorrhageGastrointestinal disorders3/880/88
PneumoniaInfections and infestations0/883/88
Upper gastrointestinal haemorrhageGastrointestinal disorders2/880/88
Acute myocardial infarctionCardiac disorders0/882/88
SepsisInfections and infestations0/882/88
AnaemiaBlood and lymphatic system disorders2/881/88
Renal failure acuteRenal and urinary disorders2/880/88
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders1/881/88
Acute pulmonary oedemaRespiratory, thoracic and mediastinal disorders0/881/88
Most frequent other events
Showing 10 of 51
Most frequent other events
EventBeriplex® P/NFresh Frozen Plasma
ConstipationGastrointestinal disorders10/884/88
AnaemiaBlood and lymphatic system disorders9/889/88
HypokalaemiaMetabolism and nutrition disorders7/888/88
NauseaGastrointestinal disorders7/884/88
HypotensionVascular disorders7/886/88
Oedema peripheralGeneral disorders6/886/88
Atrial fibrillationCardiac disorders5/883/88
TachycardiaCardiac disorders5/881/88
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders1/885/88
PyrexiaGeneral disorders3/885/88

Baseline characteristics

The Intention-to-Treat Efficacy (ITT-E) population included all randomized participants who had received any study product, underwent the intended surgical procedure, and had an INR \> 1.3 prior to the infusion. Participants in the ITT-E population were analyzed 'as randomized'.

Age, Customized
Age, Customized(participants)Beriplex® P/NFresh Frozen PlasmaTotal
< 65 years323971
>= 65 to < 75 years211940
>= 75 years342357
Sex: Female, Male
Sex: Female, Male(Participants)Beriplex® P/NFresh Frozen PlasmaTotal
Female373168
Male5050100
08

Study locations

30 sites
  • Study Site
    Newark, Delaware 19718, United States
  • Study site
    Lexington, Kentucky 40536, United States
  • Study Site
    Boston, Massachusetts 02114, United States
  • Study Site
    Duluth, Minnesota 55805, United States
  • Study Site
    Minneapolis, Minnesota 55415, United States
  • Study Site
    Albuquerque, New Mexico 87131, United States
  • Study Site
    Rochester, New York 14642, United States
  • Study Site
    Winston-Salem, North Carolina 27157, United States
  • Study Site
    Philadelphia, Pennsylvania 19107, United States
  • Study Site
    West Reading, Pennsylvania 19611, United States
  • Study Site
    Wilkes Barre, Pennsylvania 18711, United States
  • Study Site
    Memphis, Tennessee 38163, United States
  • Study Site
    Austin, Texas 78701, United States
  • Study site
    Bryan, Texas 77802, United States
  • Study Site
    El Paso, Texas 79905, United States
  • Study Site
    Houston, Texas 77030, United States
  • Study Site 1
    Minsk, Belarus
  • Study Site 2
    Minsk, Belarus
  • Study Site
    Rousse, 7002, Bulgaria
  • Study Site 4
    Sofia, 1606, Bulgaria
  • Study Site
    Varna, 9010, Bulgaria
  • Study Site
    Beirut, 2833-7401, Lebanon
  • Study Site
    Saida, 652, Lebanon
  • Study Site
    Timisoara, 300736, Romania
  • Study Site 2
    Barnaul, 656038, Russian Federation
  • Study Site
    Kazan, 420012, Russian Federation
  • Study Site 1
    Moscow, 105203, Russian Federation
  • Study Site 2
    Moscow, 125206, Russian Federation
  • Study Site
    Novosibirsk, 630051, Russian Federation
  • Study Site
    Saint Petersburg, 192242, Russian Federation
09

References and documents

Publications

  • Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015 May 23;385(9982):2077-87. doi: 10.1016/S0140-6736(14)61685-8. Epub 2015 Feb 27. PubMed 25728933 ↗
  • Refaai MA, Goldstein JN, Lee ML, Durn BL, Milling TJ Jr, Sarode R. Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal. Transfusion. 2015 Nov;55(11):2722-9. doi: 10.1111/trf.13191. Epub 2015 Jul 1. PubMed 26135740 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Nov 2012 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 1 year 3 months after primary completion. A results delay was requested in Nov 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2008
First posted
Dec 5, 2008
Start
Feb 2009
Primary completionActual
Nov 2012
CompletionActual
Feb 2013
Results delay requested
Nov 7, 2013
Results first posted
Feb 25, 2014
Last update
Apr 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00803101
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Dec 5, 2008
Start date
Feb 2009
Primary completion
Nov 2012
Completion
Feb 2013
Results posted
Feb 25, 2014
Last update
Apr 6, 2015

Study contacts

Program Director, Clinical R&D
study director · CSL Behring
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Prothrombin complex concentrate · Four-factor Prothrombin Complex Concentrate

Start the discussion